P&T COMMITTEE MEETING

Agenda October 8, 2019
1:00 p.m. – 5:00 p.m.

303 E. 17th Ave, 7th Floor Conference room (7ABC), Denver, CO 80203

☐ Committee Member Introductions

Unfinished Business and General Orders

- Approval of minutes from July 9th, 2019 P&T meeting
- Update on Diabetes Management Classes – DPP-4 Inhibitors
- Update on Diabetes Management Classes – GLP-1 Analogues
- Update on Diabetes Management Classes – Hypoglycemic Combos
- Update on Diabetes Management Classes – SGLT-2 Inhibitors
- Update on Anticonvulsants, Oral
- Update on Colony Stimulating Factors
- Update on Erythropoiesis Stimulating Proteins
- Update on Newer Hereditary Angioedema (HAE) Agents
- Update on Ophthalmic Immunomodulators
- Update on Anticoagulants
- Update on Contraceptives, Oral
- Update on GI Motility, Chronic
- Update on Stimulants and other ADHD Agents
- Update on Mass review drug classes:
  - Bone Resorption Suppression and Related Agents
  - Diabetes Management Classes – Amylin
  - Diabetes Management Classes – Biguanides
  - Diabetes Management Classes – Meglitinides
  - Diabetes Management Classes – TZDs
  - Overactive Bladder Agents
  - Prenatal Vitamins

New Business

1. P&T Committee member term expirations and open positions
   a. Open Positions for January 2020
i. Pharmacist (2 positions)
ii. Other Specialty Physician (3 positions)
iii. Member Representative (1 position)

2. Updates from the Prior Authorization Call Center
3. Policy and Procedure update

Drug Classes Up for Review:
- Review of Anti-Emetics
- Review of Anti-Platelets
- Review of Antipsoriasis (Oral and Topical)
- Review of Epinephrine Auto-Injector Products
- Review of Hepatitis C Virus Treatments - Direct-Acting Antivirals
- Review of NSAIDs (Oral and Non-Oral)
- Review of Pulmonary Arterial Hypertension (PAH) Agents
  - Endothelial Antagonists
  - Guanylate Cyclase
  - Phosphodiesterase Inhibitors
  - Prostanoids
- Review of Targeted Immune Modulators (TIMs)
- Review of Non-Biologic Ulcerative Colitis Agents (Oral and Non-Oral)
- Mass review drug classes*:
  - Anti-Depressants
    - Monoamine Oxidase Inhibitors (MAOIs)
    - Newer Generation
    - Tricyclics (TCAs)
  - Anti-herpetic (Oral and Topical)
  - Anti-hyperuricemics
  - Fluoroquinolones (Oral)
  - H. Pylori Treatments
  - Hepatitis C – Single-Agent Ribavirin Products
  - Pancreatic Enzymes
  - Proton Pump Inhibitors
  - Triptans and other Migraine Treatments (Oral and Non-Oral)

Each Review will contain:
- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share and FDA updates
- Committee Discussion and Recommendations for each Class

*Mass review drug classes will only include:
- Overview for each Drug Class, including market share and FDA updates
**Upcoming Meeting Date:** Tuesday, January 7th, 2020; 1:00 p.m. – 5:00 p.m.

**Presentations:**

Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.

Please contact Brittany Schock, PDL Pharmacist, at 303-866-6371 or by email at brittany.schock@hcpf.state.co.us to give advance notice to present at the meeting. Written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jlczechowski@magellanhealth.com (carbon copy Brittany Schock) and once approved, will be distributed to all present P&T Committee Members. Please provide public comments by October 4th, 2019 for dissemination to the P&T Committee.